Sandrine Visentin, Pascal Auquier, Yves Bertrand, André Baruchel, Marie-Dominique Tabone, Cécile Pochon, Charlotte Jubert, Maryline Poirée, Virginie Gandemer, Anne Sirvent, Jacinthe Bonneau, Catherine Paillard, Claire Freycon, Justyna Kanold, Virginie Villes, Julie Berbis, Claire Oudin, Claire Galambrun, Isabelle Pellier, Geneviève Plat, Hervé Chambost, Guy Leverger, Jean-Hugues Dalle and Gérard Michel.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2003-2010.

https://pubmed.ncbi.nlm.nih.gov/27522039/

We compared the long-term impact of donor type (sibling donor [SD] versus matched unrelated donor [MUD] or umbilical cord blood [UCB]) on late side effects and quality of life (QoL) in childhood acute leukemia sur-vivors treated with hematopoietic stem cell transplantation. We included 314 patients who underwenttransplantation from 1997 to 2012 and were enrolled in the multicenter French Leucémie de l’Enfant et deL’Adolescent (“Leukemia in Children and Adolescents”) cohort. More than one-third of the patients were adultsat last visit; mean follow-up duration was 6.2 years. At least 1 late effect was observed in 284 of 314 patients(90.4%).

The average number of adverse late effects was 2.1±.1, 2.4±.2, and 2.4±.2 after SD, MUD, and UCBtransplantation, respectively. In a multivariate analysis, considering the SD group as the reference, we did notdetect an impact of donor type for most sequelae, with the exception of increased risk of major growth failureafter MUD transplantation (odds ratio [OR], 2.42) and elevated risk of osteonecrosis after UCB transplanta-tion (OR, 4.15).

The adults and children’s parents reported comparable QoL among the 3 groups. Adult patientQoL scores were lower than age- and sex-matched French reference scores for almost all dimensions. We con-clude that although these patients are heavily burdened by long-term complications, donor type had a verylimited impact on their long-term health status and QoL.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2003-2010.

https://pubmed.ncbi.nlm.nih.gov/27522039/

Consult other publications

40. Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling

39. Misconceptions and beliefs around hormone replacement therapy after childhood hematopoietic stem cell transplantation: A qualitative study among women leukemia survivors

38. Ovarian Function and Spontaneous Pregnancy After Hematopoietic Stem Cell Transplantation for Leukemia Before Puberty: An L.E.A. Cohort Study

37. Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort

36. The uterine volume is dramatically decreased after hematopoietic stem cell transplantation during childhood regardless of the conditioning regimen

35. Brothers and sisters of childhood acute leukemia survivors: Their long-term quality of life and its determinants

34. Bone mineral density evolution and its determinants in long-term survivors of childhood acute leukemia: a L.E.A. study

33. Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study

32. Quality of life in parents of childhood leukemia survivors. A French Childhood Cancer Survivor Study for Leukemia study.

31. Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia.

30. Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors’ cohort: a comparison with controls from the French population.

29. Adolescence and Socioeconomic Factors: Key Factors in the Long-Term Impact of Leukemia on Scholastic Performance—A LEA Study.

28. Metabolic Syndrome Among Leukemia Survivors: Still Delineating the Risk.

27. A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers – DeNaCaPST programme.

26. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program.

25. Metabolic syndrome in long-term survivors of childhood acute leukemia treated without hematopoietic stem cell transplantation: an L.E.A. study.

24. Employment in French young adult survivors of childhoodleukemia: an LEA study (for Leucemies de l’Enfant et de l’Adolescent—childhood and adolescent leukemia)

22. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.

21. Educational and occupational outcomes of childhood cancer survivors 30 years afterdiagnosis: a French cohort study.

20. Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

19. Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.

18. Quality of life in minor siblings of childhood leukemia survivors, long-term after diagnosis: A LEA study (for Leucemies de l’Enfant et de l’Adolescent – childhood and adolescent leukemia).

17. Late cardiomyopathy in childhood acute myeloid leukemia survivors: an L.E.A. study.

16. Childhood cancer survivor cohorts in Europe.

15. Health status and quality of life of long-term survivors of childhood acute leukemia: the impact of central nervous system irradiation.

14. Cohort Profile: The French Childhood Cancer Survivor Study For Leukaemia (LEA Cohort).

13. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.

12. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

11. Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.

10. Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.

9. A French Cohort of Childhood Leukemia Survivors: Impact of Hematopoietic Stem Cell Transplantation on Health Status and Quality of Life.

8. Adherence to Leukemia Maintenance Therapy: A Comparative Study Among Children, Adolescents, and Adults.

7. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

6. Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-UpStudy (LEA).

5. Bone mineral density in adult-survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.

4. Quality of life in a heterogeneous sample of caregivers of cancer patients: an in-depth interview study.

3. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia.

2. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.

1. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation.